View all Hu-Lieskovan S publications in the NIH PubMed Database
Selected Publications
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan L. Cell. 2020 Oct 15;183(2):347-362.e24. doi: 10.1016/j.cell.2020.08.053. PMID: 33064988
Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM. JAMA Dermatol. 2020 Sep 1;156(9):1004-1011. doi: 10.1001/jamadermatol.2020.1729. PMID: 32725204
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. Torrejon DY, Abril-Rodriguez G, Champhekar AS, Tsoi J, Campbell KM, Kalbasi A, Parisi G, Zaretsky JM, Garcia-Diaz A, Puig-Saus C, Cheung-Lau G, Wohlwender T, Krystofinski P, Vega-Crespo A, Lee CM, Mascaro P, Grasso CS, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Ribas A. Cancer Discov. 2020 Aug;10(8):1140-1157. doi: 10.1158/2159-8290.CD-19-1409. Epub 2020 May 28. PMID: 32467343
Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. McKean WB, Moser JC, Rimm D, Hu-Lieskovan S. Am Soc Clin Oncol Educ Book. 2020 May;40:e275-e291. doi: 10.1200/EDBK_280571. PMID: 32453632 Free article.
Mechanisms of Resistance to PD-1 Checkpoint Blockade. Moser, JC, Hu-Lieskovan S. Drugs (2020), 80(5), 459-465.
Persistence of Adoptively Transferred T Cells With a Kinetically Engineered IL-2 Receptor Agonist. Parisi G, Saco J, Salazar F, Tsoi J, Krystofinski P, Puig-Saus C, Zhang R, Zhou J, Cheung-Lau G, Garcia A, Grasso C, Tavaré R, Hu-Lieskovan S, Mackay S, Zalevsky J, Bernatchez C, Diab A, Wu A, Comin-Anduix B, Charych D & Ribas A. Nat Communications (2020), 11(1).
Real-World Survival of Patients With Advanced BRAF V600 Mutated Melanoma Treated With Front-Line BRAF/MEK Inhibitors, anti-PD-1 Antibodies, or Nivolumab/Ipilimumab. Moser J, Chen D, Hu-Lieskovan S, Grossmann K, Patel S, Colonna S, Ying J, Hyngstrom J.. Cancer Medicine (2019), 8 (18), 7637-7643.
Can Pegylated IL-10 Add to a Backbone of PD-1 Inhibition for Solid Tumours? Pal S, Hu-Lieskovan S, Agarwal N. Lancet Oncology (2019), 20(11), 1473-1474.
Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. Zhu Y, Smith D, Zhou Y, Li Y, Yu J, Lee D, Wang Y, Biase S, Wang X, Hardoy C, Ku J, Tsao T, Lin L, Pham A, Moon H, McLaughlin J, Cheng D, Hollis R, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali M, Gjertson D, Wang X, Galic Z, Kitchen S, An DS, Hu-Lieskovan S, Kaplan-Lefko P, Oliveria S, Seet C, Larson S, Forman S, Heath J, Zack J, Crooks G, Radu C, Ribas A, Kohn D, Witte O, Yang L. Cell Stem Cell (2019), 25(4), 542-557.e9.
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer. Hu-Lieskovan S, Lisberg A, Zaretsky J, Grogan T, Rizvi H, Wells D, Carroll J, Cummings A, Madrigal J, Jones B, Gukasyan J, Shintaku IP, Slamon D, Dubinett S, Goldman J, Elashoff D, Hellmann M, Ribas A, Garon E. Clinical Cancer Research (2019), 25(16), 5061-5068.
Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial. Johnson ML, Braiteh F, Grilley-Olson JE, Chou J, Davda J, Forgie A, Li R, Jacobs I, Kazazi F, Hu-Lieskovan S. JAMA Oncology (2019), 5(7), 999-1007.
Safety and Clinical Activity of PD-L1 Blockade in Patients With Aggressive Recurrent Respiratory Papillomatosis. Allen CT, Lee S, Norberg S, Kovalovsky D, Ye H, Clavijo P, Hu-Lieskovan S, Schlegel R, Schlom J, Strauss J, Gulley J, Trepel J, Hinrichs CS. Journal of Immunotherapy Cancer (2019), 7 (1), 119.
Immunogenicity of Immunomodulatory, Antibody-Based, Oncology Therapeutics. Davda J, Declerck P, Hu-Lieskovan S, Hickling T, Jacobs IA, Chou J, Salek-Ardakani S, Kraynov E. Journal of Immunotherapy Cancer (2019), 7(1), 105.
A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy With Dendritic Cell Vaccination With or Without Ipilimumab. Nowicki TS, Berent-Maoz B, Cheung-Lau G, Huang RR, Wang X, Tsoi J, Kaplan-Lefko P, Cabrera P, Tran J, Pang J, Macabali M, Garcilazo IP, Carretero IB, Kalbasi A, Cochran AJ, Grasso CS, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, Singh A, Ribas A. Clinical Cancer Research (2019), 25(7), 2096-2108.
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? Fares C, Van Allen EM, Drake C, Allison JP, Hu-Lieskovan S. American Society of Clinical Oncology Education Book (2019), 39, 147-164.
Isolation and Characterization of NY-ESO-1-specific T Cell Receptors Restricted on Various MHC Molecules. Bethune MT, Li XH, Yu J, McLaughlin J, Cheng D, Mathis C, Moreno BH, Woods K, Knights AJ, Garcia-Diaz A, Wong S, Hu-Lieskovan S, Puig-Saus C, Cebon J, Ribas A, Yang L, Witte ON, Baltimore D. Proceedings of the National Acadamy of Sciences U S A (2018), 115(45), E10702-E10711.
Age Correlates With Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Kugel CH 3rd, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kuma V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT. Clinical Cancer Research (2018), 24(21), 5347-5356.
Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, Nowak JA, Nishihara R, Qian ZR, Inamura K, Morikawa T, Nosho K, Abril-Rodriguez G, Connolly C, Escuin-Ordinas H, Geybels MS, Grady WM, Hsu L, Hu-Lieskovan S, Huyghe JR, Kim YJ, Krystofinski P, Leiserson MDM, Montoya DJ, Nadel BB, Pellegrini M, Pritchard CC, Puig-Saus C, Quist EH, Raphael BJ, Salipante SJ, Shin DS, Shinbrot E, Shirts B, Shukla S, Stanford JL, Sun W, Tsoi J, Upfill-Brown A, Wheeler DA, Wu CJ, Yu M, Zaidi SH, Zaretsky JM, Gabriel SB, Landaer ES, Garraway LA, Hudson TJ, Fuchs CS, Ribas A, Ogino S, Peters U. Cancer Discovery (2018), 8(6), 730-749.
High Response Rate to PD-1 Blockade in Desmoplastic Melanomas. Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, Liniker E, Kong B, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku IP, Wei C, Sosman JA, Joseph RW, Postow MA, Carlino MS, Hwu WJ, Scolyer RA, Messina J, Cochran AJ, Long GV, Ribas A. Nature (2018), 553 (7688), 347-350.
Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Nowicki TS, Hu-Lieskovan S, Ribas A. The Cancer Journal (2018), 24(1), 47-53.
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors. Tolcher AW, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaik A, Rasco DW, Di Gravio D, Huang B, Gambhire D, Chen Y, Thall AD, Pathan N, Schmidt EV, Chow LQM.. Clinical Cancer Research (2017), 23(18), 5349-5357.
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, Parisi G, Saus CP, Torrejon DY, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Damoiseaux R, Lo RS, Ribas A. Cell Reports (2017), 19(6), 1189-1201.
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Cell Reports (2017), 168(4), 707-723.
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Rodriguez GA, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA Jr, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas A. Cancer Discovery (2017), 7(2), 188-201.
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS. Cell (2017), 168(3), 542.
New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone. Hu-Lieskovan S, Ribas A. The Cancer Journal (2017), 23(1), 10-22.
What does PD-L1 positive or negative mean? Ribas A, Hu-Lieskovan S. Journal of Experimental Medicine (2016), 213 (13), 2835-2840.
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. Homet Moreno B, Zaretsky JM, Garcia-Diaz A, Tsoi J, Parisi G, Robert L, Meeth K, Ndoye A, Bosenberg M, Weeraratna AT, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Ribas A. Cancer Immunology Research (2016), 4(10), 845-857.
Mutations Associated With Acquired Resistance to PD-1 Blockade in Melanoma. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Moreno BH. The New England Journal of Medicine (2016), 375(9), 819-29.
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS. Cell (2016), 165(1), 35-44.
Combining Targeted Therapy With Immunotherapy. Can 1+1 Equal More Than 2? Robert L, Ribas A, Hu-Lieskovan S. Seminars in Immunology (2016) 28(1), 73-80.
Combined Treatment With Dabrafenib and Trametinib With Immune-Stimulating Antibodies for BRAF Mutant Melanoma. Homet Moreno B, Mok S, Comin-Anduix B, Hu-Lieskovan S, Ribas A. OncoImmunology (2016), 5(7), e1052212.
Excluding T Cells: Is β-Catenin the Full Story? Hu-Lieskovan S, Homet Moreno B, Ribas A. Cancer Cell (2015), 27(6), 749-50.
Inhibition of Colony Stimulating Factor-1 Receptor Improves Antitumor Efficacy of BRAF Inhibition. Mok S, Tsoi J, Koya R, Hu-Lieskovan S, West BL, Bollag G, Graeber TG, Ribas A. BMC Cancer (2015), 15, 356.
Improved Antitumor Activity of Immunotherapy With BRAF and MEK Inhibitors in BRAF(V600E) Melanoma. Hu-Lieskovan S, Mok S, Moreno BH, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B, Ribas A. Sci Transl Med (2015), 7(279), 279ra41.
Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges. Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A. Journal of Clinical Oncology (2014), 32(21), 2248-54.
EGF61 Polymorphism Predicts Complete Pathologic Response to Cetuximab-Based Chemoradiation Independent of KRAS Status in Locally Advanced Rectal Cancer Patients. Hu-Lieskovan S, Vallbohmer D, Zhang W, Yang D, Pohl A, Labonte MJ, Grimminger PP, Hölscher AH, Semrau R, Arnold D, Dellas K, Debucquoy A, Haustermans K, Machiels JP, Sempoux C, Rödel C, Bracko M, Velenik V, Lenz HJ. Clinical Cancer Research (2011), 17(15), 5161-9.
A let-7 microRNA-binding Site Polymorphism in 3'-untranslated Region of KRAS Gene Predicts Response in Wild-Type KRAS Patients With Metastatic Colorectal Cancer Treated With Cetuximab Monotherapy. Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, Lurje G, LaBonte MJ, Wilson PM, Gordon MA, Hu-Lieskovan S, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ. Annals of Oncology (2011), 22(1), 104-9.
The EWS/FLI1 Oncogenic Transcription Factor Deregulates GLI1. Zwerner JP, Joo J, Warner KL, Christensen L, Hu-Lieskovan S, Triche TJ, May WA. Oncogene (2008), 27(23), 3282-91.
Sequence-Specific Knockdown of EWS-FLI1 by Targeted, Nonviral Delivery of Small Interfering RNA Inhibits Tumor Growth in a Murine Model of Metastatic Ewing's Sarcoma. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Cancer Research (2005), 65(19), 8984-92.
A Nanoparticle-based Model Delivery System To Guide the Rational Design of Gene Delivery to the Liver. 2. In Vitro and In Vivo Uptake Results. Popielarski SR, Hu-Lieskovan S, French SW, Triche TJ, Davis ME. Bioconjugate Chemistry (2005), 16(5), 1071-80.
EWS-FLI1 Fusion Protein up-regulates Critical Genes in Neural Crest Development and Is Responsible for the Observed Phenotype of Ewing's Family of Tumors. Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ. Cancer Research (2005), 65(11), 4633-44.
Lack of Interferon Response in Animals to Naked siRNAs. Heidel JD, Hu S, Liu XF, Triche TJ, Davis ME. Nature Biotechnology (2004), 22(12), 1579-82.
Selective Usage of D-Type Cyclins by Ewing's Tumors and Rhabdomyosarcomas. Zhang J, Hu S, Schofield DE, Sorensen PH, Triche TJ. Cancer Research (2004), 64(17), 6026-34.